Mirvaso

How to order Mirvaso

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Mirvaso on Prescriptsy

Mirvaso is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Mirvaso is a topical gel containing brimonidine tartrate 3 mg/g (equivalent to 0.33% brimonidine), a selective alpha-2 adrenergic receptor agonist licensed in the United Kingdom for the symptomatic treatment of persistent facial erythema (redness) in adults with rosacea.

Mirvaso works by constricting the dilated superficial blood vessels in the facial skin that produce the characteristic redness and flushing of rosacea.

It provides temporary but clinically meaningful reduction in visible redness, with onset within 30 minutes and duration of up to 12 hours.

Rosacea is a chronic inflammatory skin condition affecting an estimated 1 in 10 people in the UK, most commonly fair-skinned adults aged 30 to 50.

Persistent facial erythema is the hallmark feature of erythematotelangiectatic rosacea (subtype I) and is frequently present in other rosacea subtypes alongside papules, pustules, or tissue thickening.

This page provides a comprehensive clinical overview of Mirvaso, including how it works, correct application technique, side effects, important safety warnings, and how to obtain a prescription in the UK.

Important safety information about Mirvaso

Before reading further, note the following key safety points about Mirvaso.

• Mirvaso provides temporary relief of facial redness only. It does not treat the inflammatory component of rosacea (papules and pustules).
• Rebound erythema (worsening redness as the gel wears off) can occur in some patients and may limit long-term use.
• Avoid contact with the eyes, eyelids, lips, and nasal mucosa.
• Use with caution if you have cardiovascular disease, depression, Raynaud's phenomenon, or are taking medicines that lower blood pressure.

What is rosacea

Rosacea is a chronic, relapsing inflammatory skin disorder that predominantly affects the central face, including the cheeks, nose, forehead, and chin.

It is characterised by episodes of flushing, persistent erythema (redness), visible blood vessels (telangiectasia), and, in inflammatory subtypes, papules and pustules resembling acne.

In some patients, long-standing rosacea can lead to rhinophyma (thickening of the skin of the nose) or ocular involvement (blepharitis, conjunctivitis, or keratitis).

The exact cause of rosacea is not fully understood, but it involves a combination of neurovascular dysregulation (abnormal control of facial blood vessel dilation), innate immune system dysfunction (increased cathelicidin and kallikrein activity), environmental triggers, and possibly Demodex folliculorum mite overpopulation.

The neurovascular component is particularly relevant to Mirvaso, as the persistent erythema results from chronic dilation of superficial dermal blood vessels, which brimonidine targets directly.

Rosacea in the UK

Rosacea affects an estimated 5.5 million adults in the UK and is most common in people with fair skin, particularly those of Northern European descent.

It typically presents between the ages of 30 and 50 and is slightly more common in women, although men are more likely to develop rhinophyma.

Rosacea is often underdiagnosed and undertreated, with many patients attributing their symptoms to sensitive skin, sun damage, or flushing.

NICE Clinical Knowledge Summaries provide guidance on the diagnosis and management of rosacea in primary care.

How Mirvaso works: mechanism of action

Brimonidine is a highly selective alpha-2 adrenergic receptor agonist.

Alpha-2 adrenoceptors are found on the smooth muscle cells of blood vessels throughout the body, including the superficial dermal vasculature of the face.

When brimonidine binds to these receptors, it stimulates vasoconstriction, reducing the diameter of the dilated blood vessels and decreasing the flow of blood through the superficial vascular plexus.

This reduces the visible redness and warmth associated with rosacea erythema.

The pharmacokinetic profile of topical brimonidine gel is characterised by a rapid onset of vasoconstriction (within 30 minutes), peak effect at approximately 3 to 6 hours post-application, and gradual return of erythema over the following 6 to 12 hours as the drug is metabolised and eliminated.

The effect is entirely symptomatic; brimonidine does not modify the underlying inflammatory or neurovascular pathology of rosacea, and the redness returns when treatment is stopped.

Systemic absorption of brimonidine after topical facial application is low but measurable. Plasma concentrations remain well below those achieved with ophthalmic brimonidine.

However, the potential for systemic alpha-2 agonist effects (including lowered blood pressure and heart rate) means that caution is warranted in patients with cardiovascular or cerebrovascular disease.

Clinical evidence and national guidelines

The efficacy of Mirvaso was established in two pivotal Phase III randomised, double-blind, placebo-controlled trials (Studies 1 and 2) involving over 550 patients with moderate to severe facial erythema associated with rosacea.

Both studies demonstrated statistically significant reductions in erythema assessed by both clinician and patient scales at 3, 6, 9, and 12 hours post-application.

Approximately 25 to 30% of patients achieved a two-grade or greater improvement on both the clinician erythema assessment and the patient self-assessment at peak effect, compared with 10 to 15% in the vehicle group.

Post-marketing experience has highlighted the issue of rebound erythema in a proportion of patients.

Some users report worsening redness that exceeds their baseline level as the gel wears off, which may occur within hours of application or progressively over days of repeated use.

This phenomenon has been documented in case reports and post-marketing safety data. Prescribers should inform patients about this possibility and recommend a trial period to assess individual response.

Current rosacea management guidelines from NICE CKS, the British Association of Dermatologists (BAD), and European consensus recommendations position brimonidine gel as a treatment option for persistent erythema in rosacea, typically used alongside anti-inflammatory treatments for patients who have both redness and papulopustular lesions.

Application guidance

Mirvaso should be applied once daily to the face. Before application, wash and dry your face gently using a mild, fragrance-free cleanser. Avoid abrasive scrubs, toners, or astringents, as these may irritate rosacea-prone skin.

How to apply

Dispense a small, pea-sized amount of gel for each of the five areas of the face: the forehead, the chin, the nose, the right cheek, and the left cheek.

This gives a total of approximately five pea-sized amounts (roughly 1 gram of gel). Spread the gel smoothly and evenly across each area in a thin layer.

Avoid the eyes, eyelids, lips, inside of the nose, and any area of broken or irritated skin.

Wash your hands thoroughly immediately after application to prevent accidental transfer of the gel to the eyes or other sensitive areas.

Combining with other products

Allow Mirvaso to dry completely before applying cosmetics, sunscreen, or other skincare products.

If you use other topical rosacea treatments (such as metronidazole, ivermectin, or azelaic acid), apply them at a different time of day to avoid interaction or dilution.

Your prescriber can advise on the best routine for combining treatments.

Side effects of Mirvaso

Common side effects

Erythema at the application site is the most commonly reported side effect, which may seem counterintuitive for an anti-redness product.

This can manifest as a flushing reaction or as rebound erythema when the vasoconstrictive effect wears off.

Some patients find that the redness that returns is more intense or widespread than their usual baseline, which may limit the product's usefulness.

Flushing (a transient sensation of warmth and redness), burning or stinging at the application site, and skin dryness or tightness are also commonly reported.

Uncommon side effects

Contact dermatitis (allergic or irritant) can develop, particularly with repeated use. Symptoms include worsening redness, itching, scaling, or a rash at the application site.

If this occurs, discontinue use and consult your prescriber. Eyelid swelling and pallor (excessive whitening of treated skin) have been reported uncommonly.

Worsening of papules and pustules has also been noted in some patients.

Systemic side effects

Systemic effects are rare with topical use but may include headache, dry mouth, nasal dryness or congestion, and mild hypotension.

These are more likely in patients applying excessive amounts of gel or using the product on large areas. Patients with pre-existing cardiovascular conditions should be monitored.

When to seek medical advice

Contact your GP, pharmacist, or NHS 111 if you experience worsening redness that does not return to baseline, signs of allergic reaction (rash, swelling, difficulty breathing), significant skin irritation, or visual disturbance if the gel has contacted your eyes.

Seek emergency care by calling 999 if you experience symptoms of a severe allergic reaction including throat swelling, difficulty breathing, or widespread hives.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Rebound erythema

Rebound erythema is the most discussed concern with Mirvaso.

In some patients, the facial redness that returns as the gel wears off is more severe than the pre-treatment baseline.

This may occur on the first day of use or develop gradually over weeks of daily application.

If rebound erythema occurs, discuss with your prescriber whether to continue, reduce the frequency of application, or discontinue treatment entirely.

Strategies such as applying Mirvaso only on specific occasions (rather than daily) or using a thinner layer may help some patients.

Cardiovascular caution

Although systemic absorption is low, brimonidine is a vasoconstrictor with potential cardiovascular effects.

Use Mirvaso with caution if you have severe or unstable cardiovascular disease, coronary insufficiency, cerebrovascular disease, Raynaud's phenomenon, orthostatic hypotension, or scleroderma.

Concurrent use with antihypertensives, beta-blockers, or cardiac glycosides may increase the risk of hypotension or bradycardia.

Concomitant use with monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants is not recommended.

Eye contact

Brimonidine was originally developed as an eye drop for glaucoma and can cause miosis (pupil constriction), conjunctival blanching, and reduced intraocular pressure if it contacts the eyes.

Take care to avoid the periorbital area during application. If gel accidentally enters the eye, rinse thoroughly with clean water. If visual symptoms persist, seek medical advice.

Pregnancy and breastfeeding

There are no adequate data on the use of brimonidine gel during pregnancy.

Animal studies have not indicated direct harmful effects on fertility or foetal development at clinically relevant doses, but caution is advised.

Discuss with your prescriber before using Mirvaso if you are pregnant or planning a pregnancy. Brimonidine is excreted in breast milk.

A decision should be made whether to discontinue breastfeeding or discontinue Mirvaso treatment, taking into account the importance of treatment to the mother.

How to get a Mirvaso prescription in the UK

Mirvaso is classified as a prescription-only medicine (POM) in the UK.

It can be prescribed by your GP, a dermatologist, or an authorised online prescriber registered with the GPhC.

A clinical assessment of your rosacea subtype and severity is needed before prescribing, to ensure that Mirvaso is appropriate and that any inflammatory component is also being treated.

The standard NHS prescription charge in England is currently 9.90 pounds per item. Prescriptions are free in Scotland, Wales, and Northern Ireland. Mirvaso may also be available via private prescription.

Living with rosacea: practical management

Rosacea is a chronic condition that requires ongoing management. In addition to pharmacological treatment, the following lifestyle measures can help to reduce flares and control symptoms.

Identify and avoid your personal triggers using a rosacea diary.

Common triggers include sun exposure, hot drinks, spicy foods, alcohol, extremes of temperature, wind, stress, hot baths, and certain skincare products.

Use a broad-spectrum sunscreen with SPF 30 or higher every day, as ultraviolet radiation is one of the most common and potent rosacea triggers.

Choose gentle, fragrance-free cleansers and moisturisers formulated for sensitive or rosacea-prone skin.

Avoid products containing alcohol, witch hazel, menthol, camphor, or sodium lauryl sulphate, as these can irritate the skin.

Green-tinted colour-correcting primers or foundations can help to camouflage residual redness when used alongside medical treatment.

When to seek urgent medical advice

Most rosacea is managed in primary care, but seek medical advice promptly if you develop eye symptoms (redness, grittiness, burning, light sensitivity, or blurred vision), as ocular rosacea can damage the cornea if untreated.

Contact your GP or NHS 111 if your rosacea is worsening despite treatment, if you develop new large pustules or nodules, or if your condition is significantly affecting your mental health or quality of life.

Referral to a dermatologist may be appropriate for moderate to severe rosacea or for cases not responding to standard treatments.

Report any suspected adverse reactions to Mirvaso via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Mirvaso 3 mg/g gel, Summary of Product Characteristics (EMC)
• Brimonidine tartrate, British National Formulary (BNF)
• NICE CKS: Rosacea
• British Association of Dermatologists: Rosacea
• Rosacea, NHS
• MHRA Yellow Card Scheme